PICK A TIME SLOT
₹ 1100
Dwarka - Delhi
Book an appointment for Consultation
Afternoon
Evening
Doctor Consultation Charges (Hospital Visit)- Rs. 1100/-
Doctor Consultation Charges (Video Consultation) - Rs. Price not Available/-
₹ 1100--
You will receive an SMS with a verification code on this number.
Are you new to hospital ?
We have sent you an OTP on
Resend OTP
Did not receive OTP? You can request for another OTP. Click on Resend OTP
Go Back
Your appointment is
confirmed.
The details will be shared via Email & SMS
Note :Temporary visitor restriction, only one attendant is permitted with the patient. Your cooperation is solicited.
-
-
-
-
-
-
Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.
Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies.
Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.
In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.
- Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
- Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
- Head and Neck Cancers
- Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
- Breast cancer
- Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
- Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
- Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
- Myeloma, Lymphomas, Leukemias
- Bone and Soft Tissue Tumors (Sarcomas)
- And other rare or less common solid tumors (Melanoma, Skin Cancers)
- Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
- Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
- Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
- Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
- Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
- Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.
- European Society of Medical Oncology
- American Society of Medical Oncology
- Indian Society of Medical and Pediatric Oncology
- English
- Hindi
- Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
- Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.
- Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
- An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
- An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
- Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
- Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
- Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
- Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
- Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
- A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
- VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
- Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
- M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075
Overview
Field of Expertise
Fellowship & Membership
Languages Spoken
Awards & Achievements
Talks & Publications
- European Society of Medical Oncology
- American Society of Medical Oncology
- Indian Society of Medical and Pediatric Oncology
Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.
Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies.
Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.
In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.
- Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
- Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
- Head and Neck Cancers
- Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
- Breast cancer
- Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
- Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
- Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
- Myeloma, Lymphomas, Leukemias
- Bone and Soft Tissue Tumors (Sarcomas)
- And other rare or less common solid tumors (Melanoma, Skin Cancers)
- Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
- Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
- Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
- Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
- Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
- Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.
- English
- Hindi
- Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
- Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.
- Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
- An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
- An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
- Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
- Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
- Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
- Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
- Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
- A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
- VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
- Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
- M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075
Fellowship & Membership
Overview
Field of Expertise
Languages Spoken
Awards & Achievements
Talks & Publications
- English
- Hindi
Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.
Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies.
Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.
In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.
- European Society of Medical Oncology
- American Society of Medical Oncology
- Indian Society of Medical and Pediatric Oncology
- Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
- Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
- Head and Neck Cancers
- Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
- Breast cancer
- Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
- Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
- Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
- Myeloma, Lymphomas, Leukemias
- Bone and Soft Tissue Tumors (Sarcomas)
- And other rare or less common solid tumors (Melanoma, Skin Cancers)
- Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
- Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
- Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
- Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
- Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
- Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.
- Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
- Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.
- Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
- An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
- An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
- Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
- Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
- Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
- Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
- Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
- A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
- VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
- Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
- M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075
Languages Spoken
Overview
Fellowship & Membership
Field of Expertise
Awards & Achievements
Talks & Publications
- Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
- Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
- Head and Neck Cancers
- Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
- Breast cancer
- Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
- Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
- Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
- Myeloma, Lymphomas, Leukemias
- Bone and Soft Tissue Tumors (Sarcomas)
- And other rare or less common solid tumors (Melanoma, Skin Cancers)
- Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
- Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
- Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
- Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
- Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
- Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.
- European Society of Medical Oncology
- American Society of Medical Oncology
- Indian Society of Medical and Pediatric Oncology
- English
- Hindi
- Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
- Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.
- Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
- An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
- An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
- Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
- Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
- Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
- Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
- Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
- A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
- VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
- Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
- M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075
Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.
Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies.
Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.
In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.
Field of Expertise
Fellowship & Membership
Languages Spoken
Awards & Achievements
Talks & Publications
Overview
- Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
- Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.
- European Society of Medical Oncology
- American Society of Medical Oncology
- Indian Society of Medical and Pediatric Oncology
- Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
- Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
- Head and Neck Cancers
- Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
- Breast cancer
- Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
- Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
- Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
- Myeloma, Lymphomas, Leukemias
- Bone and Soft Tissue Tumors (Sarcomas)
- And other rare or less common solid tumors (Melanoma, Skin Cancers)
- Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
- Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
- Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
- Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
- Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
- Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.
- English
- Hindi
- Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
- An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
- An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
- Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
- Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
- Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
- Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
- Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
- A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
- VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
- Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
- M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075
Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.
Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies.
Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.
In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.
Awards & Achievements
Fellowship & Membership
Field of Expertise
Languages Spoken
Talks & Publications
Overview
- Extraadrenal Pheochromocytoma-case report of refractory hypertension. Singh VP, Singh M, Malhotra M, Kumar A, Agarwal AK. Indian heart J. Mar Apr; 64(2):203-5
- An uncommon cause of bilateral peripheral facial nerve paralysis. Singh VP, Jain V, Malhotra M, Agarwal AK, Arya V. Natl Med J India. 2010 Sep-oct;23(5):312
- An unusual complication of liver abscess. Singh VP, Agarwal AK, Malhotra M, Teengh DP, JIACM 2011;12(1):73-5
- Prevalence of diabetic retinopathy in type 2 diabetes and its correlation with various clinical and metabolic factors. Malhotra M, Lal AK, Singh VP, Malik PK, Arya V, Agarwal AK, Ind J Dia Dev Ctries 2014. DOI 10.1007/s13410-013- 0183-6.
- Extranodal NK/T-cell lymphoma of the nasal type with predominant T call markers: A rare subtype of rare disease entity. Intl Journal of Medicine and Public Health. Varshney A Nanadan, Patidar R, Malhotra M, Behera M, Nagar M, Kataria SP. 2015;5(4):378-380.
- Outcomes with second line chemotherapy in advanced pancreatic cancers - a retrospective study from a tertiary cancer centre in India; Ind J Can. Ramaswamy A, Parthiban S, Malhotra M, Kothari R,Goel A, Bhargava P, et al. Indian J Cancer 2018;55:144-7.
- Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and
- Vomiting in Patients with Glioma. Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM. Clinical Onclogy. Volume 31, Issue 1, page e85
- A cross-sectional audit of distress in patients undergoing adjuvant therapy or follow-up in central nervous system malignancies. Patil VM, Malhotra M, Tonse R, Deodhar J, Chandrasekharan A, Pande N, Bhattacharjee A, Jalali R; Neuro- Oncology Practice, npy046.
- VM Patil, A Chandrasekharan, DH Vallathol, M Malhotra, R Abhinav, P Agarwal, A Rajpurohit, R Tonse, A Bhattacharjee, R Jalali, Antiemetic prophylaxis with temozolomide: an audit from a tertiary care centre, Neuro-Oncology Practice,, npz009, https://doi.org/10.1093/nop/npz009
- Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation. S Wadhwa,G Krishna, M Malhotra, K Prabhash, V Noronha, A Joshi, V Patil, A Mahajan. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz066,https://doi.org/10.1093/annonc/mdz066
- M Malhotra, V Noronha, A Joshi, V Patil, S Wadhwa, K Prabhash. Real-world experience of ALK positive NSCLC from India, Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz063.075, https://doi.org/10.1093/annonc/mdz063.075
Dr. Mridul Malhotra specialises in treating cancer with compassion, expertise, and innovation. With a focus on personalised medicine and the latest advancements in oncology, Dr. Mridul is dedicated to delivering the highest quality of care to our patients. He has extensive experience in diagnosing and treating cancers and is one of the best medical oncologists in Delhi. His journey in oncology began with a passion for understanding the complexities of cancer biology and a commitment to improving patient outcomes through evidence-based medicine. He is the foremost Cancer Specialist in Delhi.
Dr. Mridul Malhotra is at the forefront of precision medicine, utilizing genomic testing and molecular profiling to tailor treatment plans for each patient. By identifying specific genetic mutations driving tumour growth, he can recommend targeted therapies that offer the greatest chance of success while minimizing side effects. He collaborates closely with surgeons, radiation oncologists, pathologists, and other specialists to develop comprehensive treatment strategies.
Compassion and empathy are at the core of Dr. Mridul’s practice. He takes the time to listen to each patient's concerns, preferences, and goals, empowering them to be active participants in their care journey. Whether discussing treatment options, managing side effects, or providing emotional support, Dr. Mridul is dedicated to ensuring that every patient feels heard, supported, and valued.
In addition to this, he regularly hosts educational seminars and workshops for patients, caregivers, and healthcare professionals to raise awareness about cancer prevention, early detection, and treatment advances. Leveraging the power of digital marketing, Dr. Mridul maintains an active presence on social media platforms, sharing informative content, patient testimonials, and updates on the latest advancements in oncology. He actively participates in community events, health fairs, and cancer awareness initiatives to raise visibility for Manipal Hospital and promote cancer prevention and early detection.
- European Society of Medical Oncology
- American Society of Medical Oncology
- Indian Society of Medical and Pediatric Oncology
- Precision Oncology: Tailoring treatment plans for cancer patients based on genomic testing and molecular profiling.
- Solid Tumor Management: Specializing in the diagnosis and treatment of solid tumors, including but not limited to:
- Head and Neck Cancers
- Thoracic Cancers (Lung Cancer, Esophageal(Cancer of Food Pipe), Mesothelioma)
- Breast cancer
- Gastrointestinal Cancers (Hepatobiliary Cancers, Pancreatic Cancer, Gastric Cancer, Colorectal Cancers)
- Urological Malignancies (Renal Cell Carcinoma, Urothelial Malignancies, Testicular Tumors)
- Gynaecological Malignancies(Cervix, Uterine Cancer, Ovaries, Vulva, etc)
- Myeloma, Lymphomas, Leukemias
- Bone and Soft Tissue Tumors (Sarcomas)
- And other rare or less common solid tumors (Melanoma, Skin Cancers)
- Immunotherapy: Utilizing cutting-edge immunotherapeutic agents to harness the body's immune system to fight cancer, improving treatment outcomes and quality of life for patients across various solid tumour types.
- Palliative Care: Offering compassionate support and symptom management for patients with advanced or terminal cancer, including those with solid tumours.
- Patient Advocacy: Empowering patients to make informed decisions about their care and advocating for their needs within the healthcare system, including access to treatments for all types of solid tumours.
- Global Health Initiatives: Participating in international conferences, research collaborations, and medical missions to address cancer disparities and improve access to treatments for solid tumours worldwide.
- Leadership and Mentorship: Guiding medical students, residents, and fellows in oncology training programs and serving as a leader in the field of solid tumour management and immunotherapy.
- Continuous Learning: Staying abreast of the latest advancements in oncology and immunotherapy through ongoing education, research, and professional development, with a focus on addressing the diverse needs of patients with solid tumours.
- English
- Hindi
- Dr. Mridul garnered prestigious travel grants for his poster presentation at the European Lung Cancer Congress (ELCC) 2019, focusing on the real-world experience of ALK-positive NSCLC patients in India. The presentation shed light on novel insights into ALK-positive NSCLC management, emphasizing Dr. Mridul's commitment to advancing oncology research and patient care. https://doi.org/10.1093/annonc/mdz063.075
- Dr. Mridul was honored with travel grants for ESMO Asia 2017(Singapore) for his/her paper presentation at the Indian Cancer Congress 2017 in Bengaluru. The presentation delved into outcomes with second-line chemotherapy in advanced pancreatic cancers, drawing from a retrospective study conducted at a Tata Memorial Hospital, Mumbai in India.
Talks & Publications
Overview
Fellowship & Membership
Field of Expertise
Languages Spoken
Awards & Achievements
Refund Policy
1) Up to 4 hrs of appointment time:
Rescheduling of doctor appointment can be done within a week from the date of appointment as per doctor / slot availability.
Cancellation can be done with full refund of the payment.
2) Up to 2 hrs of appointment time:
Rescheduling of doctor appointment can be done within a week from the date of appointment as per doctor / slot availability.
Cancellation of appointment and refund with a cancellation charge of Rs.100/-.
3) Less than 2 hrs of appointment time:
Rescheduling / cancellation of appointment cannot be done, payment non-refundable in this case. However, Units can have the discretion to refund / reschedule in case of exigencies.
Please note : While making the payment online, above mentioned payment terms and conditions should be agreed upon by customers, by clicking in a box ( I agree) and then proceed for payment.
PATIENT CONSENT FOR TELEMEDICINE / TELECONSULTATION
Telemedicine involves the use of electronic communications to enable Hospitals/health care centres to provide healthcare services at different locations through exchange of information and for the purpose of improving patient care. I, confirm that I have received the necessary information to sign this form and I agree to take part in a live telemedicine/teleconsultation session with Manipal Hospitals.
I understand that:
- Interactive audio/video connection, electronic information and communication technologies shall be used for providing me with a telemedicine/teleconsultation.
- In case the information obtained via teleconsultation is not sufficient to make a diagnosis, I may be required to go to Manipal Hospitals for in-person consultation.
- Though the telemedicine/teleconsultation is private, other individuals, medical and non-medical, may be present to facilitate the consultation and that they will take reasonable steps to maintain confidentiality of the information obtained.
- A limited visual examination will take place during the telemedicine/teleconsultation and that it cannot replace a full medical examination done physically at Manipal Hospitals.
- I have the right to withhold or withdraw my consent to the use of telemedicine/teleconsultation in the course of my care at any time, without affecting my right to future care or treatment. I may also revoke my consent orally or in writing at any time.
- I may be prescribed medicines for treatment or/and diagnostic tests to further evaluate my health condition. All prescription will be sent to my registered email/phone no. Manipal Hospitals will keep a record of the consultation & prescription in my medical record.
- The telemedicine/teleconsultation services are not in any way intended to be used in case of an emergency.
- There can be potential risks with this technology e.g information transmitted may not be sufficient to allow for appropriate medical decision, the video /audio may disconnect/stop in-between, security protocols could fail causing a breach of privacy of personal medical information.
- Any relevant medical information about me including details of my medical history, examinations, x-rays, tests, photographs or other images may be transmitted /shared by Manipal Hospitals with their staff, specialist, business partners for the purpose of record, communications, feedback, enquires, follow ups, analysis etc.
- Manipal Hospitals responsibility shall terminate upon conclusion of this teleconference.
- I hereby consent that in consideration for the telemedicine / teleconsultation services rendered to me, I agree to pay the relevant charges.
- I hereby release Manipal Hospitals, its personnel and any other person participating in my care from any and all liability which may arise from authorized use of such Video / E-Consultation, Videotapes, Digital recording films and Photographs. I have read this document and understand the risk of the telemedicine / teleconsultation.
- I hereby consent to participate in a telemedicine / teleconsultation under the terms & conditions described in this document.
